BUZZ-Beam Therapeutics rises after FDA clears genetic disorder drug application

Reuters03-28

** Biotech firm Beam Therapeutics' BEAM.O shares rise 5.6% to $23.43 premarket

** BEAM said late on Thursday that the U.S. FDA has cleared its marketing application for its experimental drug, BEAM-302, to treat a type of genetic disorder called alpha-1 antitrypsin deficiency (AATD)

** AATD is a rare genetic disorder associated with a considerable burden of lung and liver disease, and for which there are no currently approved curative treatments, co says

** Brokerage BofA Global Research says data from the drug's clinical trial, though early-stage, is "potentially practice-changing"

** Brokerage remains positive on the market for AATD with more than $5 billion unadjusted peak sales

** Thirteen of 17 brokerages rate the stock "buy" or higher, 4 "hold"

** As of last close, BEAM has fallen ~35% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment